

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A mesothelioma therapeutic agent that contains an interleukin-6 (IL-6) antagonist as its active ingredient.
2. (Original) A mesothelioma therapeutic agent according to claim 1 wherein, the mesothelioma is pleural mesothelioma.
3. (Original) A mesothelioma therapeutic agent according to claim 2 wherein, the pleural mesothelioma is malignant pleural mesothelioma.
4. (Currently Amended) A mesothelioma therapeutic agent according to ~~any of claims 1 through 3~~ Claim 1 wherein, the IL-6 antagonist is antibody to IL-6 receptor.
5. (Original) A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to IL-6 receptor.
6. (Original) A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to human IL-6 receptor.
7. (Original) A mesothelioma therapeutic agent according to claim 4 wherein, the antibody to IL-6 receptor is monoclonal antibody to mouse IL-6 receptor.
8. (Currently Amended) A mesothelioma therapeutic agent according to ~~any of claims 4 through 7~~ Claim 4 wherein, the antibody to IL-6 receptor is recombinant antibody.
9. (Original) A mesothelioma therapeutic agent according to claim 6 wherein, the monoclonal antibody to human IL-6 receptor is PM-1 antibody.
10. (Original) A mesothelioma therapeutic agent according to claim 7 wherein, the monoclonal antibody to mouse IL-6 receptor is MR16-1 antibody.

11. (Currently Amended) A mesothelioma therapeutic agent according to ~~any of claims 4 through 10~~ Claim 4 wherein, the antibody to IL-6 receptor is chimeric antibody, humanized antibody or human antibody.

12. (Original) A mesothelioma therapeutic agent according to claim 11 wherein, the humanized antibody to IL-6 receptor is humanized PM-1 antibody.

13. (Original) A growth inhibitor against mesothelioma cells that contains an interleukin-6 (IL-6) antagonist as its active ingredient.

14. (Original) A growth inhibitor according to claim 13 wherein, the mesothelioma is pleural mesothelioma.

15. (Original) A growth inhibitor according to claim 14 wherein, the pleural mesothelioma is malignant pleural mesothelioma.

16. (Currently Amended) A growth inhibitor according to ~~any of claims 13 through 15~~ Claim 13 wherein, the IL-6 antagonist is antibody to IL-6 receptor.

17. (Original) A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to IL-6 receptor.

18. (Original) A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to human IL-6 receptor.

19. (Original) A growth inhibitor according to claim 16 wherein, the antibody to IL-6 receptor is monoclonal antibody to mouse IL-6 receptor.

20. (Currently Amended) A growth inhibitor according to ~~any of claims 16 through 19~~ Claim 16 wherein, the antibody to IL-6 receptor is recombinant antibody.

21. (Original) A growth inhibitor according to claim 18 wherein, the monoclonal antibody to human IL-6 receptor is PM-1 antibody.

22. (Original) A growth inhibitor according to claim 19 wherein, the monoclonal antibody to mouse IL-6 receptor is MR16-1 antibody.

23. (Currently Amended) A growth inhibitor according to ~~any of claims 16 through 22~~ Claim 16 wherein, the antibody to IL-6 receptor is chimeric antibody, humanized antibody or human antibody.

24. (Original) A growth inhibitor according to claim 23 wherein, the humanized antibody to IL-6 receptor is humanized PM-1 antibody.